PCM
CADX

Prelude Capital Management’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Prelude Capital Management’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-3,800
Closed -$34K – 2330
2013
Q4 		$34K Buy
+3,800
New +$27.4K 0.01% 1241

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Prelude Capital Management's CADX Position: Q1 2014 in Review

Prelude Capital Management sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 3,800 shares — an estimated $34K sold.

Prelude Capital Management first reported a position in CADX in Q4 2013 and held it in 1 quarter. The position peaked at $34K in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Prelude Capital Management reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Prelude Capital Management sold 3,800 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $34K.
  • Prelude Capital Management first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q4 2013 and held it in 1 quarter.
  • Prelude Capital Management's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $34K in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Prelude Capital Management's 13F filing for Q1 2014, filed 15 May 2014.